Dose of Corticosteroids in COPD (DOSE)

This study is currently recruiting participants.

See

Contacts and Locations

Verified September 2016 by Jeffrey L Carson, MD, Rutgers, The State University of New Jersey

Sponsor:

Information provided by (Responsible Party):

Jeffrey L Carson, MD, Rutgers, The State University of New Jersey

ClinicalTrials.gov Identifier:

NCT01742338

First received: December 3, 2012

Last updated: September 29, 2016

Last verified: September 2016

History of Changes

Purpose

COPD (chronic obstructive pulmonary disease) is a long-lasting lung disease usually caused by long-term smoking. COPD can get worse, making people sick enough to need hospitalization. Corticosteroids are very effective and are almost always used, but nobody knows the right dose. High doses may work better but could cause more side effects than low doses. Typical treatment lengths last at least one week. This study will be comparing two common regimens: either 40mg of corticosteroids daily (low dose), or 80mg of corticosteroids daily (high dose). It is unknown which regimen works better..

Condition	Intervention	Phase
COPD	Drug: Low Dose Corticosteroids Drug: High Dose Corticosteroids	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Determining Optimal Dose of Corticosteroids in COPD Exacerbations: A Pilot Study

Resource links provided by NLM:

MedlinePlus related topics: Steroids

U.S. FDA Resources

Further study details as provided by Jeffrey L Carson, MD, Rutgers, The State University of New Jersey:

Primary Outcome Measures:

Treatment Failure [ Time Frame: 30 days ]
Composite outcome of treatment failure defined as death, intubation, re-admission for COPD exacerbation, or intensification of therapy (increased steroid use, change of antibiotic therapy) within a 30-day follow-up period.

Secondary Outcome Measures:

Length of Stay [ Time Frame: 30 days ]
Length of hospital stay
Quality of Life [ Time Frame: 30 days ]
Quality of life measured by Clinical COPD Questionnaire. The Clinical COPD Questionnaire consists of 10 questions about the severity of COPD symptoms and limitation of activities over the prior week.

Other Outcome Measures:

Adverse Effects [ Time Frame: 30 days ]
Composite outcome of short-term adverse effects. Defined as hyperglycemia, hypertension, adrenal suppression, psychiatric disturbance, infection, and gastrointestinal bleed that require a consultation, an invasive procedure, or initiation of a specific therapy.


Estimated Enrollment:	125
Study Start Date:	May 2012
Estimated Study Completion Date:	July 2018
Estimated Primary Completion Date:	June 2018 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Low Dose Corticosteroids 10 mg IV q8hrs x 3 days, then prednisone 40 mg PO daily x 4 days, then prednisone 30 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then prednisone 10 mg daily x 1 day, then stop. If patient unable to receive IV medications, will give prednisone 20 mg PO bid for the first 3 days.	Drug: Low Dose Corticosteroids Other Names: prednisone methylprednisolone Solumedrol
Experimental: High Dose Corticosteroids Methylprednisolone 40 mg IV q8hrs x 3 days, then prednisone 80 mg PO daily x 4 days, then prednisone 60 mg daily x 1 day, then prednisone 40 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then stop. If patient unable to receive IV medications, will give prednisone 40 mg PO bid for the first 3 days.	Drug: High Dose Corticosteroids Other Names: prednisone methylprednisolone Solumedrol

Detailed Description:

The goal of the study is to determine whether a high-dose corticosteroid regimen in patients admitted to the hospital with COPD exacerbations is associated with better clinical outcomes and at acceptable risk of adverse effects compared to a low-dose corticosteroid regimen. Our hypothesis is that high-dose corticosteroids is associated with a decreased rate of treatment failure, shorter length of hospital stay, and improved quality of life with similar risk of adverse effects. The study population includes patients ≥ 40 years-old with a ≥ 10 pack-years smoking history and a diagnosis of COPD, emphysema, or chronic bronchitis who present to the emergency room with increased dyspnea, increased sputum, or increased cough that requires admission to the hospital. We will perform a prospective, randomized, double-blinded study to determine if a high-dose corticosteroid regimen, which is already in use in clinical practice, decreases treatment failure compared to a low-dose corticosteroid regimen that is based on national consensus guidelines.

Eligibility


Ages Eligible for Study:	40 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

i. Patients with a diagnosis of COPD, emphysema, or chronic bronchitis ii. Age ≥ 40 years-old iii. Smoking history ≥ 10 pack-years iv. Presentation to the emergency room with increased dyspnea, increased sputum, or increased cough v. Admission to the hospital

Exclusion Criteria:

i. Alternative diagnosis for cause of dyspnea, increased sputum or cough ii. Patients who requires intubation at time of recruitment iii. Patients who are unable to give consent iv. Patients who are pregnant or could be pregnant or are currently breast-feeding v. Women of child-bearing age who cannot use methods of contraception as described in the consent, including condoms, female condoms, cervical caps, diaphragms, and intra uterine devices.

vi. Patients who were previously entered into the trial and are re-admitted to the hospital with a new COPD exacerbation.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01742338

Contacts


Contact: Jeffrey L Carson, MD	732-235-7122	jeffrey.carson@rutgers.edu
Contact: Helaine Noveck, MPH	732-235-6581	helaine.noveck@rutgers.edu

Locations


United States, New Jersey
Robert Wood Johnson University Hospital	Recruiting
New Brunswick, New Jersey, United States, 08901
Principal Investigator: Jeffrey L Carson, MD
University Medical Center at Princeton	Not yet recruiting
Plainsboro, New Jersey, United States, 08536
Contact: Kenneth Goldblatt, MD 609-853-7272 kgoldblatt@princetonhcs.org
Contact: Van Pham, MD 732-668-2712 vanpham316@gmail.com
Principal Investigator: Kenneth Goldblatt, MD

Sponsors and Collaborators

University of Medicine and Dentistry of New Jersey

Investigators


Principal Investigator:	Jeffrey L Carson, MD	Rutgers, The State University of New Jersey

More Information


Responsible Party:	Jeffrey L Carson, MD, Professor of Medicine, Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier:	NCT01742338 History of Changes
Other Study ID Numbers:	0220120019
Study First Received:	December 3, 2012
Last Updated:	September 29, 2016

Keywords provided by Jeffrey L Carson, MD, Rutgers, The State University of New Jersey:


Chronic Obstructive Pulmonary Disease COPD Chronic bronchitis emphysema Corticosteroids

Additional relevant MeSH terms:


Prednisolone acetate Methylprednisolone acetate Prednisone Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone Prednisolone hemisuccinate Prednisolone phosphate Anti-Inflammatory Agents Glucocorticoids Hormones	Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Neuroprotective Agents Protective Agents

ClinicalTrials.gov processed this record on July 26, 2017

To Top